Your browser doesn't support javascript.
Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang, Yuanyuan; Zhong, Yanyan; Pan, Lin; Dong, Jing.
  • Zhang Y; Department of Rheumatology and Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Zhong Y; Department of Rheumatology and Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Pan L; Department of Rheumatology and Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Dong J; Department of Rheumatology and Clinical Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Drug Discov Ther ; 14(2): 100-102, 2020.
Article in English | MEDLINE | ID: covidwho-176018
ABSTRACT
The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine storm" in COVID-19. However, we still lack reliable studies to verify "cytokine storm" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Receptors, Interleukin-6 / Antibodies, Monoclonal, Humanized Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Drug Discov Ther Year: 2020 Document Type: Article Affiliation country: Ddt.2020.03006

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Receptors, Interleukin-6 / Antibodies, Monoclonal, Humanized Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Drug Discov Ther Year: 2020 Document Type: Article Affiliation country: Ddt.2020.03006